Year: 2020
Type: article
Study design: Observational Study
Abstract: You have accessJournal of UrologyPenile & Testicular Cancer: Penile & Testicular Cancer III (MP76)1 Apr 2020MP76-02 SINGLE INSTITUTION EXPERIENCE WITH PRIMARY RPLND FOR LOW-STAGE SEMINOMA Richard Matulewicz*, Darren Feldman, Samuel Funt, Nicole Benfante, Brett Carver, and Joel Sheinfeld Richard Matulewicz*Richard Matulewicz* More articles by this author , Darren FeldmanDarren Feldman More articles by this author , Samuel FuntSamuel Funt More articles by this author , Nicole BenfanteNicole Benfante More articles by this author , Brett CarverBrett Carver More articles by this author , and Joel SheinfeldJoel Sheinfeld More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000962.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Low stage seminoma of the testis with suspected retroperitoneal lymph nodes metastases has traditionally been managed with primary chemotherapy or radiation therapy with excellent cancer specific outcomes. However, increased appreciation of the long-term morbidity profile associated with these treatments has raised concerns. Primary RPLND in these patients may allow for more precise staging and can potentially avoid or reduce the exposure to chemotherapy or radiation. METHODS: Following IRB approval, all patients with testicular seminoma undergoing primary RPLND for the treatment of suspected retroperitoneal node(s) were retrospectively identified from a single institution’s prospectively collected database. Patient demographics, oncologic staging information, peri-operative details, pathologic diagnoses, and adjuvant treatment and recurrence outcomes were collected and described. RESULTS: In total, 12 patients were identified (Table 1). Of these, 9 were CSI seminoma that recurred in the RP during surveillance and 3 were CSII seminoma at presentation. For relapsing CSI patients, all were treated with RPLND for “early recurrences” (7 mo median time to recurrence) with median pre-operative RP node size 1.9cm (cN1=5, cN2=4). For CSII patients, 2 patients were cN1 and 1 was cN2. All RPLNDs were bilateral template. Median number of LN removed was 61 (range 27-159) and median number of positive nodes was 2 (range 1-6). Two patients were pN0, one patient had teratoma (pN1) and all others were seminoma (1 pN1, 8 pN2). In total, 7 patients were managed with post-RPLND observation and 5 received chemotherapy (all EPx2). To date, none have recurred with a median follow up time of 11 months (range 1-166 months) (Table 2). CONCLUSIONS: These preliminary data suggest that primary RPLND for clinically node positive pure seminoma is a safe and efficacious treatment option that may avoid or reduce exposure to chemo or radiotherapy. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1151-e1152 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Richard Matulewicz* More articles by this author Darren Feldman More articles by this author Samuel Funt More articles by this author Nicole Benfante More articles by this author Brett Carver More articles by this author Joel Sheinfeld More articles by this author Expand All Advertisement PDF downloadLoading ...
Source: The Journal of Urology
Authors: Richard Matulewicz*, Darren Feldman, Samuel Funt, Nicole Benfante, Brett Carver, Joel Sheinfeld
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3021075144